TFF1 and pancreatic adenocarcinoma: Only recently, the de novo expression of TFF1 has been associated with gemcitabine resistance in pancreatic adenocarcinomas, and TFF1 silencing increased sensitivity to gemcitabine in vitro and in vivo [42].